OpenEvidence has reportedly raised $250 million in a financing that values the medical-AI startup at $15 billion, extending a rapid run of fundraising as major AI companies push deeper into healthcare.
Business Insider reports that hospital systems and Andreessen Horowitz supplied the new investment, citing people familiar with the matter. OpenEvidence did not announce the terms publicly in the report, so the size, valuation and investor details remain attributed to the outlet's sources.
A third valuation jump in less than two years
The reported price is a step up from January, when OpenEvidence raised another $250 million at a $12 billion valuation. That earlier deal followed valuations of $6 billion in October 2025 and $1 billion in February 2025. Business Insider now says the company has raised more than $1 billion over the past year.
The $15 billion figure is the valuation assigned to the company in the transaction; it is not the amount OpenEvidence raised or a measure of its revenue. The latest round adds $250 million in capital.
OpenEvidence sells access to an AI-powered medical information and search system designed for clinicians. The company says its platform is used across more than 10,000 U.S. care centers and draws on medical publishing partnerships, though those company claims are separate from the financing report.
A possible sale is still only a possibility
Business Insider also reports that OpenEvidence could be open to selling itself, with access to computing capacity cited as one potential reason. But the outlet says it could not verify interest from any prospective acquirer and notes that the company may prefer to remain independent.
That distinction matters because the financing is described as a completed investment, while any acquisition is speculative. The report arrives as OpenAI, Anthropic and other model developers expand their own healthcare products, increasing both the strategic value of established clinician-facing services and the competition around them.
Technology